The Kidney Cancer Program seeks to conduct innovative basic research into the molecular and biological basis for various cancers of the kidney with the goals of identifying: 1) meaningful biomarkers for early detection, prognosis and treatment selection;2) novel factors associated with either innate or acquired resistance to existing therapies that could be targets for future therapeutic development;and 3) new therapeutic targets. In addition, the Program seeks to conduct cutting-edge clinical trials across all disease strata in the hopes of identifying more effective treatments, used either alone or in combination, and better ways of predicting who should receive each therapy. It also aims to better understand the factors contributing to kidney cancer development and the relative cost effectiveness of various diagnosfic and treatment approaches. Finally, the Kidney Cancer Program will to continue to educate, train and promote the career advancement of the next generation of kidney cancer investigators. The Program has five Specific Aims: 1. identify and validate novel targets for renal cell carcinoma (RCC) and other cancers of the kidney 2. Identify biomarkers for early detection, prognosis and treatment selection 3. Identity mechanisms for and opportunities for overcoming resistance to existing RCC therapies 4. Explore novel immunotherapies, either alone of in combination, in patients with advanced RCC 5. Investigate the epidemiology of RCC and cost effectiveness of treatment for this disease. The Program was first approved and funded by the NCI CCSG in 2005, at which time it received a score of """"""""Excellent to Outstanding"""""""" merit. The Program has 36 members from six DF/HCC institutions, seven departments of HMS and one department of HSPH. In 2009, total peer-review funding totaled $3.8 million (total costs), of which $3 million was from the NCI. During the project period (2006 to 2010), members published 371 papers, of which 15% were intra-programmatic , 41% were inter-programmatic and 27% were inter-institutional.

Public Health Relevance

Cancers of the kidney are the second most common cancer of the genitourinary tract with over 50,000 new cases diagnosed annually accounting forever 13,000 deaths. This program seeks to understand the molecular basis for various cancers of the kidney in order to enhance early detection and treatment selection and devise better therapies that together can reduce the pain and suffering related to these cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA006516-47
Application #
8227631
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2012-05-15
Budget End
2012-11-30
Support Year
47
Fiscal Year
2012
Total Cost
$91,148
Indirect Cost
$69,350
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25
Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233
Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252
Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62
Sievers, Quinlan L; Gasser, Jessica A; Cowley, Glenn S et al. (2018) Genome-wide screen identifies cullin-RING ligase machinery required for lenalidomide-dependent CRL4CRBN activity. Blood 132:1293-1303
Kelley, Katherine A; Wieghard, Nicole; Chin, Yuki et al. (2018) MiR-486-5p Downregulation Marks an Early Event in Colorectal Carcinogenesis. Dis Colon Rectum 61:1290-1296
Yao, Lina; Seaton, Sarah Craven; Ndousse-Fetter, Sula et al. (2018) A selective gut bacterial bile salt hydrolase alters host metabolism. Elife 7:
Jalbut, Marla M; Brunner, Andrew M; Amrein, Philip C et al. (2018) Early infectious complications among patients treated with induction compared to hypomethylating therapy for acute myeloid leukemia. Leuk Lymphoma 59:988-991
Tapela, Neo M; Peluso, Michael J; Kohler, Racquel E et al. (2018) A Step Toward Timely Referral and Early Diagnosis of Cancer: Implementation and Impact on Knowledge of a Primary Care-Based Training Program in Botswana. Front Oncol 8:187
Roemer, Margaretha G M; Redd, Robert A; Cader, Fathima Zumla et al. (2018) Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. J Clin Oncol 36:942-950

Showing the most recent 10 out of 411 publications